|
Volumn 358, Issue 2, 2008, Pages 200-203
|
Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis [16]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
RAPAMYCIN;
IMMUNOSUPPRESSIVE AGENT;
MAMMALIAN TARGET OF RAPAMYCIN;
PROTEIN KINASE;
PROTEIN KINASE INHIBITOR;
ANGIOMYOLIPOMA;
BLOOD BRAIN BARRIER;
CLINICAL TRIAL;
DISEASE ASSOCIATION;
DRUG BLOOD LEVEL;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG SAFETY;
HUMAN;
HYPERLIPIDEMIA;
KIDNEY TRANSPLANTATION;
LETTER;
LUNG FUNCTION TEST;
LYMPHANGIOLEIOMYOMATOSIS;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PERIPHERAL EDEMA;
PRIORITY JOURNAL;
TUBEROUS SCLEROSIS;
KIDNEY DISEASE;
METABOLISM;
PHASE 2 CLINICAL TRIAL;
ANGIOMYOLIPOMA;
CLINICAL TRIALS, PHASE II AS TOPIC;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY DISEASES;
LYMPHANGIOLEIOMYOMATOSIS;
PROTEIN KINASE INHIBITORS;
PROTEIN KINASES;
SIROLIMUS;
TUBEROUS SCLEROSIS;
|
EID: 38049177875
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc072500 Document Type: Letter |
Times cited : (184)
|
References (5)
|